Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia

Schizophrenia Research

Volumn 159, Issue 1, 2014, Pages 130-135

  Funk, Adam J ^a   Haroutunian, Vahram ^c   Meador Woodruff, James H ^b,d   McCullumsmith, Robert E ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

G protein coupled receptor (GPCR); G protein coupled receptor kinase (GRK); Histone deacetylase (HDAC); Kinase; Postmortem; Schizophrenia

Indexed keywords

G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 3; G PROTEIN COUPLED RECEPTOR KINASE 5; G PROTEIN COUPLED RECEPTOR KINASE 6; HALOPERIDOL DECANOATE; G PROTEIN COUPLED RECEPTOR KINASE; HALOPERIDOL; NEUROLEPTIC AGENT;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CINGULATE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PH; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; CINGULATE GYRUS; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASES; GENE EXPRESSION REGULATION; GYRUS CINGULI; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84908043370     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.07.040     Document Type: Article

References (73)

1. Agis-Balboa R.C., Pavelka Z., Kerimoglu C., Fischer A. Loss of HDAC5 impairs memory function: implications for Alzheimer's disease. J. Alzheimer's Dis. 2013, 33(1):35-44.
2. Ahmed M.R., Bychkov E., Gurevich V.V., Benovic J.L., Gurevich E.V. Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. J. Neurochem. 2008, 104(6):1622-1636.
3. Ahmed M.R., Gurevich V.V., Dalby K.N., Benovic J.L., Gurevich E.V. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J. Pharmacol. Exp. Ther. 2008, 325(1):276-283.
4. Angelucci F., Brene S., Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 2005, 10(4):345-352.
5. Baracskay K., Haroutunian V., Meador-Woodruff J. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. Synapse 2006, 60(4):271-279.
6. Bauer D., Gupta D., Harotunian V., Meador-Woodruff J., McCullumsmith R. Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophr. Res. 2008, 104(1-3):108-120.
7. Bauer D.E., Haroutunian V., McCullumsmith R.E., Meador-Woodruff J.H. Expression of four housekeeping proteins in elderly patients with schizophrenia. J. Neural Transm. 2009, 116(4):487-491.
8. Bauer D., Haroutunian V., Meador-Woodruff J., McCullumsmith R. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr. Res. 2010, 117(1):92-98.
9. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63(1):182-217.
10. Bezard E., Gross C.E., Qin L., Gurevich V.V., Benovic J.L., Gurevich E.V. l-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol. Dis. 2005, 18(2):323-335.
11. Bridges T.M., Lindsley C.W. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem. Biol. 2008, 3(9):530-541.
12. Bychkov E.R., Gurevich V.V., Joyce J.N., Benovic J.L., Gurevich E.V. Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia. Neurobiol. Aging 2008, 29(3):379-396.
13. Bychkov E., Ahmed M.R., Gurevich E.V. Sex differences in the activity of signalling pathways and expression of G-protein-coupled receptor kinases in the neonatal ventral hippocampal lesion model of schizophrenia. Int. J. Neuropsychopharmacol./Off. Sci. J. Coll. Int. Neuropsychopharmacol. 2011, 14(1):1-15.
14. Bychkov E., Ahmed M.R., Gurevich E.V. Sex differences in the activity of signalling pathways and expression of G-protein-coupled receptor kinases in the neonatal ventral hippocampal lesion model of schizophrenia. Int. J. Neuropsychopharmacol. 2011, 14(1):1-15.
15. Bychkov E.R., Ahmed M.R., Gurevich V.V., Benovic J.L., Gurevich E.V. Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder. Neurobiol. Dis. 2011, 44(2):248-258.
16. Bychkov E., Zurkovsky L., Garret M.B., Ahmed M.R., Gurevich E.V. Distinct cellular and subcellular distributions of G protein-coupled receptor kinase and arrestin isoforms in the striatum. PLoS One 2012, 7(11):e48912.
17. Chawla S., Vanhoutte P., Arnold F.J., Huang C.L., Bading H. Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. J. Neurochem. 2003, 85(1):151-159.
18. Clinton S.M., Ibrahim H.M., Frey K.A., Davis K.L., Haroutunian V., Meador-Woodruff J.H. Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. Am. J. Psychiatry 2005, 162(10):1859-1871.
19. Descalzi G., Kim S., Zhuo M. Presynaptic and postsynaptic cortical mechanisms of chronic pain. Mol. Neurobiol. 2009, 40(3):253-259.
20. Dromey J.R., Pfleger K.D. G protein coupled receptors as drug targets: the role of beta-arrestins. Endocr. Metab. Immune Disord. Drug Targets 2008, 8(1):51-61.
21. Drummond J.B., Simmons M., Haroutunian V., Meador-Woodruff J.H. Upregulation of cornichon transcripts in the dorsolateral prefrontal cortex in schizophrenia. Neuroreport 2012, 23(17):1031-1034.
22. Drummond J.B., Tucholski J., Haroutunian V., Meador-Woodruff J.H. Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in anterior cingulate cortex in schizophrenia. Schizophr. Res. 2013, 147(1):32-38.
23. Emamian E., Karayiorgou M., Gogos J. Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia. J. Neurosci. 2004, 24(7):1561-1564.
24. Erdtmann-Vourliotis M., Mayer P., Ammon S., Riechert U., Hollt V. Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res. Mol. Brain Res. 2001, 95(1-2):129-137.
25. Ertley R.N., Bazinet R.P., Lee H.J., Rapoport S.I., Rao J.S. Chronic treatment with mood stabilizers increases membrane GRK3 in rat frontal cortex. Biol. Psychiatry 2007, 61(2):246-249.
26. Franklin J.M., Carrasco G.A. G-protein receptor kinase 5 regulates the cannabinoid receptor 2-induced up-regulation of serotonin 2A receptors. J. Biol. Chem. 2013, 288(22):15712-15724.
27. Funk A., Rumbaugh G., Harotunian V., McCullumsmith R., Meador-Woodruff J. Decreased expression of NMDA receptor-associated proteins in frontal cortex of elderly patients with schizophrenia. Neuroreport 2009, 20(11):1019-1022.
28. Funk A.J., McCullumsmith R.E., Haroutunian V., Meador-Woodruff J.H. Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia. Neuropsychopharmacol.: off. publ. Am. Coll. Neuropsychopharm. 2012, 37(4):896-905.
29. Gainetdinov R.R., Bohn L.M., Walker J.K., Laporte S.A., Macrae A.D., Caron M.G., Lefkowitz R.J., Premont R.T. Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice. Neuron 1999, 24(4):1029-1036.
30. Gao Y., Zhang L., Samad O., Suter M., Yasuhiko K., Xu Z., Park J., Lind A., Ma Q., Ji R. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J. Neurosci. 2009, 29(13):4096-4108.
31. Gasquoine P.G. Localization of function in anterior cingulate cortex: from psychosurgery to functional neuroimaging. Neurosci. Biobehav. Rev. 2013, 37(3):340-348.
32. Gupta D., McCullumsmith R., Beneyto M., Haroutunian V., Davis K., Meador-Woodruff J. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005, 57(3):123-131.
33. Gurevich E.V., Tesmer J.J., Mushegian A., Gurevich V.V. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol. Ther. 2012, 133(1):40-69.
34. Hammond J., McCullumsmith R., Funk A., Haroutunian V., Meador-Woodruff J. Evidence for abnormal forward trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Neuropsychopharmacology 2010, 35(10):2110-2119.
35. Harte M.K., Bachus S.B., Reynolds G.P. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophr. Res. 2005, 75(2-3):303-308.
36. Iacovelli L., Molinaro G., Battaglia G., Motolese M., Di Menna L., Alfiero M., Blahos J., Matrisciano F., Corsi M., Corti C., Bruno V., De Blasi A., Nicoletti F. Regulation of group II metabotropic glutamate receptors by G protein-coupled receptor kinases: mGlu2 receptors are resistant to homologous desensitization. Mol. Pharmacol. 2009, 75(4):991-1003.
37. Ji Y., Biernacka J.M., Hebbring S., Chai Y., Jenkins G.D., Batzler A., Snyder K.A., Drews M.S., Desta Z., Flockhart D., Mushiroda T., Kubo M., Nakamura Y., Kamatani N., Schaid D., Weinshilboum R.M., Mrazek D.A. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J. 2013, 13(5):456-463.
38. Kara E., Crepieux P., Gauthier C., Martinat N., Piketty V., Guillou F., Reiter E. A phosphorylation cluster of five serine and threonine residues in the C-terminus of the follicle-stimulating hormone receptor is important for desensitization but not for beta-arrestin-mediated ERK activation. Mol. Endocrinol. 2006, 20(11):3014-3026.
39. Kashihara K., Sato M., Fujiwara Y., Harada T., Ogawa T., Otsuki S. Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain. Biol. Psychiatry 1986, 21(7):650-656.
40. Kashihara K., Fukuda K., Sato M., Otsuki S. Haloperidol prevents the methamphetamine-induced apomorphine subsensitivity of dopamine metabolism in rat striatum. Neurosci. Res. 1987, 4(5):428-432.
41. Katsel P., Davis K.L., Gorman J.M., Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr. Res. 2005, 77(2-3):241-252.
42. Kelly E., Bailey C.P., Henderson G. Agonist-selective mechanisms of GPCR desensitization. Br. J. Pharmacol. 2008, 153(Suppl. 1):S379-S388.
43. Koppel I., Timmusk T. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors. Neuropharmacology 2013, 75:106-115.
44. Kyosseva S. Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(6):997-1006.
45. Kyosseva S. The role of the extracellular signal-regulated kinase pathway in cerebellar abnormalities in schizophrenia. Cerebellum 2004, 3(2):94-99.
46. Kyosseva S., Elbein A., Griffin W., Mrak R., Lyon M., Karson C. Mitogen-activated protein kinases in schizophrenia. Biol. Psychiatry 1999, 46(5):689-696.
47. Luo J., Busillo J.M., Benovic J.L. M3 muscarinic acetylcholine receptor-mediated signaling is regulated by distinct mechanisms. Mol. Pharmacol. 2008, 74(2):338-347.
48. Manji H.K., Gottesman I.I., Gould T.D. Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Sci. STKE 2003, (207):pe49.
49. Mateu-Huertas E., Rodriguez-Revenga L., Alvarez-Mora M.I., Madrigal I., Willemsen R., Mila M., Marti E., Estivill X. Blood expression profiles of fragile X premutation carriers identify candidate genes involved in neurodegenerative and infertility phenotypes. Neurobiol. Dis. 2014, 65C:43-54.
50. Mithani S., Martin-Iverson M.T., Phillips A.G., Fibiger H.C. The effects of haloperidol on amphetamine- and methylphenidate-induced conditioned place preferences and locomotor activity. Psychopharmacology 1986, 90(2):247-252.
51. Mithani S., Atmadja S., Baimbridge K.G., Fibiger H.C. Neuroleptic-induced oral dyskinesias: effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities. Psychopharmacology 1987, 93(1):94-100.
52. Mundell S.J., Luo J., Benovic J.L., Conley P.B., Poole A.W. Distinct clathrin-coated pits sort different G protein-coupled receptor cargo. Traffic 2006, 7(10):1420-1431.
53. Nurjono M., Lee J., Chong S.A. A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia. Clin. Psychopharmacol. Neurosci.: Off. Sci. J. Kor. Coll. Neuropsychopharmacol. 2012, 10(2):61-70.
54. Oni-Orisan A., Kristiansen L., Haroutunian V., Meador-Woodruff J., McCullumsmith R. Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol. Psychiatry 2008, 63(8):766-775.
55. Parra M., Verdin E. Regulatory signal transduction pathways for class IIa histone deacetylases. Curr. Opin. Pharmacol. 2010, 10(4):454-460.
56. Premont R.T., Gainetdinov R.R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol. 2007, 69:511-534.
57. Premont R.T., Inglese J., Lefkowitz R.J. Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J. 1995, 9(2):175-182.
58. Premont R.T., Macrae A.D., Aparicio S.A., Kendall H.E., Welch J.E., Lefkowitz R.J. The GRK4 subfamily of G protein-coupled receptor kinases. Alternative splicing, gene organization, and sequence conservation. J. Biol. Chem. 1999, 274(41):29381-29389.
59. Ren X.R., Reiter E., Ahn S., Kim J., Chen W., Lefkowitz R.J. Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(5):1448-1453.
60. Salim S., Eikenburg D.C. Role of 90-kDa heat shock protein (Hsp 90) and protein degradation in regulating neuronal levels of G protein-coupled receptor kinase 3. J. Pharmacol. Exp. Ther. 2007, 320(3):1106-1112.
61. Shenoy S.K., Drake M.T., Nelson C.D., Houtz D.A., Xiao K., Madabushi S., Reiter E., Premont R.T., Lichtarge O., Lefkowitz R.J. beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J. Biol. Chem. 2006, 281(2):1261-1273.
62. Shyu B., Vogt B. Short-term synaptic plasticity in the nociceptive thalamic-anterior cingulate pathway. Mol. Pain 2009, 5:51.
63. Suo W.Z., Li L. Dysfunction of G protein-coupled receptor kinases in Alzheimer's disease. ScientificWorldJournal 2010, 10:1667-1678.
64. Tiberi M., Nash S.R., Bertrand L., Lefkowitz R.J., Caron M.G. Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases. J. Biol. Chem. 1996, 271(7):3771-3778.
65. Todorova V., Elbein A., Kyosseva S. Increased expression of c-Jun transcription factor in cerebellar vermis of patients with schizophrenia. Neuropsychopharmacology 2003, 28(8):1506-1514.
66. Toyoda H., Zhao M., Xu H., Wu L., Ren M., Zhuo M. Requirement of extracellular signal-regulated kinase/mitogen-activated protein kinase for long-term potentiation in adult mouse anterior cingulate cortex. Mol. Pain 2007, 3:36.
67. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006, 9(4):519-525.
68. Virlon B., Firsov D., Cheval L., Reiter E., Troispoux C., Guillou F., Elalouf J.M. Rat G protein-coupled receptor kinase GRK4: identification, functional expression, and differential tissue distribution of two splice variants. Endocrinology 1998, 139(6):2784-2795.
69. Yuan P., Zhou R., Wang Y., Li X., Li J., Chen G., Guitart X., Manji H.K. Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J. Affect. Disord. 2010, 124(1-2):164-169.
70. Zhang Y., Chen L., Shen G., Zhao Q., Shangguan L., He M. GRK5 dysfunction accelerates tau hyperphosphorylation in APP (swe) mice through impaired cholinergic activity. NeuroReport 2014, 25(7):542-547.
71. Zheng H., Worrall C., Shen H., Issad T., Seregard S., Girnita A., Girnita L. Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(18):7055-7060.
72. Zhu M., Fan X.L., Yang W.L., Jiang Y., Ma L. Regulation of G protein-coupled receptor kinase 5 mRNA and protein level in rat brain by addictive drugs. Sheng li xue bao: [Acta Physiol. Sin.] 2004, 56(5):559-565.
73. Zhu W., Tilley D.G., Myers V.D., Coleman R.C., Feldman A.M. Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/beta-arrestin1/extracellular-regulated kinase 1/2-dependent pathway in H9c2 cells. Mol. Pharmacol. 2013, 84(2):227-235.